The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 111.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.50 (1.357%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 111.00
MCB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

8 Jan 2018 07:00

RNS Number : 1627B
McBride PLC
08 January 2018
 

8 January 2018

 

McBride plc

Trading Update

 

McBride plc, the leading European manufacturer and supplier of Co-manufactured and Private Label products for the Household and Personal Care market, provides its trading update for the six months ended 31 December 2017.

The Group starts its second half year with Household sales growth prospects significantly ahead of expectations but at the same time facing weak trading in the European Personal Care & Aerosols division ("PCA") and ongoing cost inflation in the near term. The combination of these factors means that the Board now expects full year earnings to be broadly in line with the prior year.

For the first half year, Group revenues at constant currency declined 0.6%. Excluding sales from Danlind, which was acquired at the end of September, underlying Household revenues were 3.4% lower versus the same period last year, with growth in the UK and South regions offset by ongoing decline in France and the negative impact in Germany of the previously-disclosed major contract loss. This reduction in revenues is now expected to be more than reversed during the second half year.

Trading at our European PCA division has been more challenging in the period and revenues declined 12.1%, approximately half of which was due to deliberate management actions to exit certain customer and product arrangements. As previously stated, we are currently developing an accelerated transformation plan for PCA and will provide more information in due course.

The lower sales levels and a number of mainly external cost challenges, including raw materials, labour market pressures and transportation costs, have impacted the Group's first half profit performance, particularly within PCA, such that adjusted operating profit for the first six months of the year will be lower than the Board's prior internal expectations. The revenue and profit performance of Danlind for its first three months as part of the Group have been in line with our expectations at the time of acquisition.

Looking ahead, the Group's growth prospects have been significantly enhanced by recent business wins, mainly arising from competitor weakness, with a number of major customers turning to the Group for support. We anticipate that these opportunities will lead to annualised high-single digit growth for the Household business. These additional sales are anticipated to phase in through the second half of the current financial year and Household is now expected to deliver mid-to-high single digit underlying revenue growth in the second half.

In order to capture this growth opportunity and support our customers, the Group has decided to defer certain efficiency and rationalisation initiatives planned for the current financial year, given the resources required in the near term to meet the anticipated rapid increase in volumes. The combination of the trading performance in the first half, ongoing cost inflation and the operational requirements of accommodating a significant level of new business means that the Group's full year adjusted profit before tax and adjusted EPS are now expected to be broadly in line with the prior year.

Although challenges remain in the European PCA business, we remain pleased with the sustained progress in our Household division, where our "Repair, Prepare, Grow" strategy is now delivering tangible benefits and the Board remains confident in the successful delivery of the Group's strategy.

Rik De Vos, Group Chief Executive, commented;

"Whilst the accelerated growth opportunity we are now seeing is an encouraging validation of the Group's strategy and the positioning of our Household business, the immediate task of accommodating such substantial growth presents challenges and choices.  Despite the near-term margin pressures we are experiencing, we remain focused on delivering our medium-term financial targets and we will re-initiate various efficiency projects once this growth has been absorbed. Additionally, restoring the performance of our PCA business, the plans for which are under consideration, remains a top priority." 

 

For further information please contact:

 

McBride plc

 

Rik De Vos, Chief Executive Officer

0161 203 7570

Chris Smith, Chief Financial Officer

0161 203 7570

 

 

FTI Consulting

020 3727 1017

Ed Bridges, Nick Hasell

 

 

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation which came into effect on 3 July 2016.

 

-Ends-

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTZDLFBVFFEBBQ
Date   Source Headline
8th Apr 202411:24 amRNSHolding(s) in Company
8th Apr 202411:22 amRNSHolding(s) in Company
5th Apr 20249:53 amRNSHolding(s) in Company
28th Mar 20243:20 pmRNSDirector/PDMR Shareholding
25th Mar 20241:52 pmRNSDirector/PDMR Shareholding
13th Mar 20247:00 amRNSCapital Markets Day
28th Feb 20242:30 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSHalf-year Report
16th Jan 20247:00 amRNSTrading Update
13th Dec 20231:47 pmRNSDirector/PDMR Shareholding
20th Nov 20235:55 pmRNSDirector/PDMR Shareholding
20th Nov 20235:39 pmRNSResult of AGM
20th Nov 20237:00 amRNSAGM Trading Update
25th Oct 202310:22 amRNSTermination of ‘upside sharing’ mechanism
19th Oct 20237:00 amRNSTrading Update
17th Oct 20235:42 pmRNSPosting of ARA and Notice of AGM
4th Oct 20235:24 pmRNSVesting of RSU Awards
29th Sep 20237:00 amRNSDirector/PDMR Shareholding
22nd Sep 20235:33 pmRNSDirector/PDMR Shareholding
21st Sep 202310:54 amRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSFinal Results
14th Jul 20237:00 amRNSFull year trading update
13th Jun 20237:00 amRNSDirector/PDMR Shareholding
31st May 20235:31 pmRNSDirectorate Change
25th May 20239:38 amRNSDirector Declaration
2nd May 20237:00 amRNSDirector/PDMR Shareholding
25th Apr 20237:00 amRNSTrading Update
11th Apr 20232:08 pmRNSDirector/PDMR Shareholding
3rd Apr 20232:39 pmRNSDirector/PDMR Shareholding
31st Mar 202312:27 pmRNSDirector/PDMR Shareholding
21st Mar 20235:59 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSHalf-year Report
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20238:46 amRNSDirector Declaration
17th Jan 20237:00 amRNSTrading Update
11th Jan 20239:01 amRNSDirector Declaration
22nd Dec 20224:23 pmRNSDirector/PDMR Shareholding
13th Dec 20222:51 pmRNSDirector/PDMR Shareholding
16th Nov 20224:42 pmRNSAGM Statement
16th Nov 20227:00 amRNSAGM Trading Update
17th Oct 20227:00 amRNSAnnual Report 2022 and Annual General Meeting 2022
5th Oct 20225:55 pmRNSDirector/PDMR Shareholding
3rd Oct 20225:07 pmRNSRedemption of B Shares
29th Sep 202212:49 pmRNSFinal Results
29th Sep 202211:51 amRNSAmended Financing Agreement
29th Sep 20227:00 amRNSPreliminary results timing
6th Sep 20222:51 pmRNSBoard Update
30th Aug 20224:35 pmRNSPrice Monitoring Extension
25th Aug 20226:22 pmRNSCorrection - Result of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.